Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc. Common Stock
- Market cap
- $256.62M
Your view on EIKN
Overview
What the company does, where it operates, and who runs it.
About Eikon Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Roger Perlmutter
- Headquarters
- 230 Harriet Tubman Way, Millbrae, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Roger Perlmutter
- Headquarters
- 230 Harriet Tubman Way, Millbrae, CA, US
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs.
It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells.
Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers.
Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Eikon Therapeutics, Inc. Common Stock. Starting points for Eikon Therapeutics, Inc. Common Stock: EPS -$6.22, beta 0.94 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Eikon Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Eikon Therapeutics, Inc. Common Stock stands at -$6.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Eikon Therapeutics, Inc. Common Stock. Eikon Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ARVNArvinas, Inc. | Healthcare | Biotechnology | $423.0M | ||
| BBOTBridgeBio Oncology Therapeutics Inc. | Healthcare | Biotechnology | $145.3M | ||
| KZIAKazia Therapeutics Limited | Healthcare | Biotechnology | $8.0M | ||
| NVCTNuvectis Pharma, Inc. | Healthcare | Biotechnology | $666.8M | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | Biotechnology | $764.9M | ||
| PRLDPrelude Therapeutics Incorporated | Healthcare | Biotechnology | $187.0M | ||
| TPSTTempest Therapeutics, Inc. | Healthcare | Biotechnology | $5.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| SCPXScorpius Holdings, Inc. | Healthcare | OTC | $130,071 | ||
| SCTXScribe Therapeutics Inc. | Healthcare | NASDAQ | $195.3M | ||
| SEERSeer, Inc. | Healthcare | NASDAQ | $75.9M | ||
| SEOVFSernova Corp. | Healthcare | OTC | $33.7M | ||
| SEPNSepterna, Inc. | Healthcare | NASDAQ | $1.8B | ||
| SEPSFAsep Medical Holdings Inc | Healthcare | OTC | $121,249 | ||
| SERSerina Therapeutics, Inc. | Healthcare | AMEX | $16.8M | ||
| SGMOQSangamo Therapeutics, Inc. | Healthcare | OTC | — | ||
| SGMTSagimet Biosciences Inc. | Healthcare | NASDAQ | $648.0M | ||
| SGPSpyGlass Pharma, Inc. Common Stock | Healthcare | NASDAQ | $1.0B | ||
| SHJBFShanghai Junshi Biosciences Co., Ltd. | Healthcare | OTC | $4.1B | ||
| SIGYSigyn Therapeutics, Inc. | Healthcare | OTC | — | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| IWOiShares Russell 2000 Growth ETF | $13.7B in assets | 0.01% | |
| TINYProShares - Nanotechnology ETF | $11M in assets | 0.64% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 0.18% | |
| OMFSInvesco Russell 2000 Dynamic Multifactor ETF | $267M in assets | 0.07% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in EIKN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Eikon Therapeutics, Inc. Common Stock, and how their positions are changing. At a $256.6M market value, institutional positions materially move Eikon Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Eikon Therapeutics, Inc. Common Stock executives and directors. Shares of Eikon Therapeutics, Inc. Common Stock have traded between $7.90 and $17.40 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Eikon Therapeutics, Inc. Common Stock. Coverage tracks Eikon Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Eikon Therapeutics, Inc. Common Stock.